Drug Uses

Ranitidine HCL is used for the treatment of active duodenal ulcer or for maintenance therapy for duodenal ulcer.

How Taken

Take Ranitidine HCL 150 mg tablets twice daily or 300 mg tablets once daily depending on how is most convenient for you. It is recommended that you take Ranitidine HCL before bedtime. Take each dose with a full glass of water.

Warnings/Precautions

If you are breast-feeding, talk to your doctor before taking Ranitidine HCL. Ranitidine HCL is secreted in human milk. Do not stop taking ranitidine without first talking to your doctor.

Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Possible Side Effects

The possible side effects that may occur during treatment with Ranitidine HCT are: constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, headache.

Storage

Store at controlled room temperature 15°-30°C (59°-86°F) in a dry place. Protect from light. Keep out of the reach of children.

Overdose

When overdosage occurs unabsorbed material has to be removed from your gastrointestinal tract. Seek emergency medical attention.

More Information

There are no restrictions on food, beverages, or activity while taking Ranitidine HCL, unless otherwise directed by your doctor.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Ranitidine-hcl at Wikipedia.org and other resources:

Analysis of heavy metal contents in gray and white MTA and 2 kinds of Portland cement: a preliminary study
Conclusion: If a clinician is considering using Portland cement versus MTA, the differences in purity may be considered. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)

Amino acid residues Arg659, Arg660, and Tyr661 in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor
Previous studies have shown that ADAMTS13 spacer domain is required for cleavage of von Willebrand factor (VWF). However, the exact amino acid residues within this domain critical for substrate recognition are not known. Epitope mapping of anti-ADAMTS13 immunoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignment of the ADAMTS13 spacer domains of human, mouse, and zebrafish with these of human and murine ADAMTS1, a closely related member of ADAMTS family, have provided hints to investigate the role of the amino acid residues between Arg659 and Glu664 of the ADAMTS13 spacer domain in substrate recognition. A deletion of all these 6 amino acid residues (ie, Arg659-Glu664) from the ADAMTS13 spacer domain resulted in dramatically reduced proteolytic activity t...

Clusters of atmospheric relevance: H2O/HCl/HNO3. Prediction of IR & MW spectra
Pedro C. Gomez, Oscar Galvez, Rafael G. Mosteo, Cristina Puzzarini, R. Escribano (Paper from Phys. Chem. Chem. Phys.) Pedro C. Gomez, Phys. Chem. Chem. Phys., 2010, DOI: 10.1039/b924890k To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Phys. Chem. Chem. Phys. latest articles)

Solid Dispersion as an Approach for Bioavailability Enhancement of Poorly Water-Soluble Drug Ritonavir.
Authors: Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J Ritonavir is an antiretroviral drug characterized by low solubility and high permeability which corresponds to BCS class II drug. The purpose of the study was to develop solid dispersion by different methods and investigate them for in vitro and in vivo performance for enhancing dissolution and bioavailability, respectively. Since the drug possesses food-related absorption, the effect of biorelevant media (FaSSIF and FeSSIF state) on dissolution behavior was also studied. The solid dispersion was prepared using Gelucire as carrier in 1:4 ratio by different methods and were characterized for differential scanning calorimetry (DSC), X-ray diffractometry, scanning electron microscopy, and FT-IR. Oral bioavailability of 10 mg of r...

Abbott Molecular - Vysis Paraffin Pretreatment Reagent Kit II - Class 2 Recall
Paraffin Pretreatment Reagent Kit II; each kit contains the following: 5 x 50 mL Pretreatment Solution (sodium thiocyanate - NaSCN), 5 x 62.5 mL Protease Buffer II (0.2N HCl), 5 x 250 mg Protease I (Pepsin, lyophilized, activity 1:3000 to 1:3500); Abbott Molecular Inc; list 07J02-002, part number 32-801210. invitro diagnostic. (Source: Medical Device Recalls since July 07, 2006)